Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
MRNA - Moderna, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$44.11
DETAILS
HIGH:
$77.00
LOW:
$25.00
MEDIAN:
$45.00
CONSENSUS:
$44.11
DOWNSIDE:
25.85%
Stock News
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.
Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Moderna wins EU contract for RSV vaccine supply
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.
Moderna Appoints Michael McDonnell to Board of Directors
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.
Moderna Stock Is Soaring. Is It Too Late to Buy?
Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
2 More Stocks to Buy for the AI Convergence
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.
An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
Price Targets
Moderna (MRNA) PT Raised to $25 at Wolfe Research
$25.00
(was $61.82)
Alexandria Hammond
·
Wolfe Research
Moderna price target raised to $39 from $33 at Morgan Stanley
$39.00
(was $79.77)
Morgan Stanley
Moderna price target raised to $45 from $38 at RBC Capital
$45.00
(was $81.80)
RBC Capital
Moderna price target raised to $77 from $69 at Piper Sandler
$77.00
(was $67.66)
Piper Sandler
Moderna price target raised to $45 from $36 at UBS
$45.00
(was $47.47)
UBS
Moderna price target raised to $38 from $35 at RBC Capital
$38.00
(was $46.87)
Luca Issi
·
RBC Capital
Moderna price target raised to $49 from $43 at Goldman Sachs
$49.00
(was $45.37)
Goldman Sachs
Moderna price target raised to $33 from $30 at Morgan Stanley
$33.00
(was $44.18)
Morgan Stanley
Jefferies Reiterates Hold Rating on Moderna (MRNA): "cash breakeven guidance is clearer"
$37.00
(was $49.83)
Andrew Tsai
·
Jefferies
Moderna price target raised to $30 from $25 at RBC Capital
$30.00
(was $42.54)
Luca Issi
·
RBC Capital
Moderna price target raised to $35 from $28 at Evercore ISI
$35.00
(was $43.19)
Cory Kasimov
·
Evercore ISI
Moderna price target raised to $45 from $35 at Bernstein
$45.00
(was $42.23)
Bernstein
Moderna price target raised to $36 from $34 at UBS
$36.00
(was $42.23)
UBS
Moderna price target raised to $30 from $28 at Morgan Stanley
$30.00
(was $42.23)
Morgan Stanley
Moderna assumed at Neutral from Buy at UBS
$34.00
(was $35.66)
UBS
Moderna price target lowered to $28 from $30 at Morgan Stanley
$28.00
(was $29.90)
Morgan Stanley
Moderna initiated with a Hold at Jefferies
$30.00
(was $29.62)
Jefferies
Moderna price target lowered to $25 from $28 at RBC Capital
$25.00
(was $23.10)
Luca Issi
·
RBC Capital
Moderna price target raised to $18 from $15 at Leerink
$18.00
(was $22.36)
UBS
Moderna price target lowered to $63 from $69 at Piper Sandler
$63.00
(was $22.36)
Piper Sandler